The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

source extracted confidence: high 2026-04-09
#adult #alanine-transaminase #anti-inflammatory-agents #antioxidants #biomarkers

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Faghihzadeh et al., 2015 | Br J Nutr | Rct

Citation

Faghihzadeh Forouzan, Adibi Payman, Hekmatdoost Azita. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015-Sep-14;114(5):796-803. doi:10.1017/S0007114515002433

Abstract

Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.

Key Findings

Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.

Outcomes Measured

  • blood pressure

Population

Field Value
Population nafld
Sample Size See abstract
Age Range See abstract
Condition blood pressure

MeSH Terms

  • Adult
  • Alanine Transaminase
  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • Blood Pressure
  • Cardiovascular Diseases
  • Dietary Supplements
  • Double-Blind Method
  • Fatty Liver
  • Female
  • Humans
  • Insulin Resistance
  • Lipid Metabolism
  • Liver
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease
  • Phytotherapy
  • Plant Extracts
  • Resveratrol
  • Risk Factors
  • Stilbenes
  • Triglycerides

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-10